1.5 -77.3%) for NGS and 20.7% (range 2.2 -44.2%) for ddPCR. The NGS and the ddPCR assays performed better than the VUC reflected by values for sensitivity of 0.78/0.69/0.67, for specificity of 0.96/1.00/ 0.96, for PPV of 0.97/1.00/0.97, for NPV of 0.67/0.61/0.58 and for accuracy of 0.83/0.79/0.76. According to this the NGS assay seems to be the best approach, but it is far more expensive (50 EUR per sample) than the ddPCR assay or the VUC (max. 3 EUR per sample).
INTRODUCTION AND OBJECTIVES: on-muscle-invasive BC (NMIBC) is a malignant disease characterized by high recurrence and progression rates, which constitutes significant challenge. At present, urinary cell-free DNA (ucf DNA) is widely considered as a potential biomarker for the noninvasive diagnosis of bladder cancer (BC) . In this study, we aimed to identify genetic signatures associated with NMIBC in ucf DNA for the progression monitoring.
METHODS: A cohort of 103 patients presenting NMIBC (pTapT1) were enrolled. The expression levels of ucf DNA IQGAP3/BMP4 and IQGAP3/FAM107A were then detected by quantitative real-time PCR analysis, and the results were correlated with clinical data using Kaplan-Meier curves and Cox regression analyses. Progression was defined as development of muscle invasion or metastasis.
RESULTS: Overall, 55 (53.4%) patients recurred and 29 (28.2%) patients progressed during the median follow-up of 43.2 (21.5-94.5) months. The High expression levels of ucf DNA IQGAP3/BMP4 and IQGAP3/FAM107A in NMIBC were associated with worse clinical outcome. Kaplan-Meier analysis showed that NMIBC patients with high IQGAP3/BMP4 lever had worse recurrence-free survival (RFS), progression-free survival (PFS) (P[0.002 and <0.001, respectively) and those with low IQGAP3/FAM107A level had better PFS (P[0.005). Multivariate Cox regression analysis revealed that IQGAP3/ BMP4 was independently associated with RFS, PFS of NMIBC (P[0.005 and 0.001 respectively), and IQGAP3/FAM107A independently related to PFS of NMIBC (P[0.048).
CONCLUSIONS: Ucf DNA IQGAP3/BMP4 and IQGAP3/ FAM107A may have considerable clinical value in prognosis prediction of BC.
Source of Funding: none

MP63-08 CD44 VARIANT 9 EXPRESSION IS A NOVEL INDICATOR FOR IDENTIFYING POOR SURVIVAL IN PATIENTS WITH INVASIVE UROTHELIAL CARCINOMA
Koichiro Ogihara*, Eiji Kikuchi, Masayuki Hagiwara, Kazuhiro Matsumoto, Shuji Mikami, Hideyuki Saya, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: CD44 is reported as major cell surface marker for cancer stem cells (CSCs) in various types of cancers. Previous studies revealed that the variant isoform of 9 (CD44v9) have been associated with their features of CSCs, which induce tumor recurrence and metastasis. However, little is known with respect to whether expression of CD44v9 could be associated with clinical outcome in !pT2 invasive urothelial carcinoma (UC). METHODS: We identified 182 patients who were treated with radical nephroureterectomy for invasive upper tract urothelial carcinoma (UTUC, n[119) or radical cystectomy for invasive bladder cancer (BC, n[63) between 1999 and 2007 at our institution and investigated the association between the expression of CD44v9 evaluated by immunohistochemical staining and their prognosis. To evaluate CD44v9 staining, cancer cells with high staining in the cell membrane were counted in at least 10 representative fields, and the mean percentage of high cancer cells was estimated.
RESULTS: The median value of the CD44v9 density was 5.5%. Patients were subsequently allocated into a CD44v9-high group (n[123) and a CD44v9-low group (n[59) based on a cut-off level of 5%. The 5-year cancer-specific survival (CSS) rate in the CD44v9-high group was 59.3%, which was significantly lower than that in the CD44v9-low group (86.4%, p<0.001). Multivariate analysis revealed that CD44v9 positivity (hazard ratio: HR, 5.18, p[0.001) was an independent risk factor for cancer-specific death in addition to high grade tumor (HR, 3.66, p[0.031) and pN positive (HR, 2.63, p[0.006). Furthermore, CD44v9 positivity (HR, 3.39, p[0.001) was independently associated with disease recurrence in addition to pN positive (HR, 3.39, p<0.001) . In a subgroup of 63 invasive BC patients, the 5-year CSS rate in the CD44v9-high group was 52.7% (n[36), which was significantly lower than that in the CD44v9-low group (n[27, 95.2%, p[0.017) and CD44v9 positivity (HR, 9.19, p[0.034) was the only independent risk factor for cancer-specific death. In a subgroup of 119 invasive UTUC patients, the 5-year CSS rate in the CD44v9-high group was 55.2% (N[87), which was significantly lower than that in the CD44v9-low group (N[32, 79.6%, p[0.017) and CD44v9 positivity (HR, 3.22, p[0.009) was the only independent risk factor for cancer-specific death. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e899
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